Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model
Open Access
- 3 January 2014
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 103, 32-38
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Experimental therapies for yellow feverAntiviral Research, 2013
- A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse modelAntiviral Research, 2012
- EXPERIMENTAL YELLOW FEVER VIRUS INFECTION IN THE GOLDEN HAMSTER (MESOCRICETUS AURATUS) III. CLINICAL LABORATORY VALUESThe American Journal of Tropical Medicine and Hygiene, 2006
- Development of a humanized monoclonal antibody with therapeutic potential against West Nile virusNature Medicine, 2005
- Passive antibody therapy for infectious diseasesNature Reviews Microbiology, 2004
- Experimental Yellow Fever Virus Infection in the Golden Hamster(Mesocricetus auratus).II. PathologyThe Journal of Infectious Diseases, 2001
- Experimental Yellow Fever Virus Infection in the Golden Hamster(Mesocricetus auratus).I. Virologic, Biochemical, and Immunologic StudiesThe Journal of Infectious Diseases, 2001
- Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain)Virology, 1987
- Lethal 17D Yellow Fever Encephalitis in Mice. I. Passive Protection by Monoclonal Antibodies to the Envelope Proteins of 17D Yellow Fever and Dengue 2 VirusesJournal of General Virology, 1986
- Pathophysiologic Correlations in a Rhesus Monkey Model of Yellow FeverThe American Journal of Tropical Medicine and Hygiene, 1981